C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
TEMESGEN Z., BURGER C., BAKER J., POLK C., LIBERTIN C., KELLEY C., MARCONI V., ORENSTEIN R., CATTERSON V., ARONSTEIN W., DURRANT C., CHAPPELL D., CHAPPELL G., AHMED O., BADLEY A.